September 14, 2022

Concerns About Acute Cholecystitis in Patients on GLP-1 RAs

Based on a series of adverse events reported to the FDA, which were in line with other research, the agency has revised prescribing information for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to include information about acute gallbladder events. According to events reported to the FDA, some patients have died from adverse effects. Learn more about what researchers have to say.


Here's What Future COVID-19 Response Might Look Like

In addition to the annual flu shot season, pharmacists might have to gear up for an annual COVID-19 shot season at the same or different time. That was the prediction of officials at a recent White House COVID-19 briefing. Find out why they predicted yearly vaccines against the novel coronavirus for most Americans, with certain vulnerable groups being boosted more frequently.

Turning Point in How Customers Use Retail Pharmacies

Acceptance of receiving health and wellness services, including vaccines, at pharmacies has grown over the last several years. In fact, a new J.D. Power survey pointed out that the majority of customers visiting pharmacies used those extra services as well as shopping and filling prescriptions. That led to a rise in customer satisfaction, as well. Read more.


When Should IV KENGREAL (cangrelor) Be Used in the Cath Lab?

The 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization has a specific recommendation: In patients undergoing percutaneous coronary intervention who are P2Y12-inhibitor naive, IV cangrelor may be reasonable to reduce periprocedural ischemic events (Class of Recommendation 2b with level of evidence B from randomized clinical trials). Read more.

Facebook   Twitter   USP Google App   USP itunes App
U.S. Pharmacist
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Advertisement Advertisement